This article is more than 5 years old. Information may no longer be current.

Lin Bioscience’s Stargardt disease treatment gets European orphan drug designation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Medicines Agency has granted orphan drug designation to Lin BioScience’s Stargardt disease treatment, the company announced in a press release.

LBS-008, an oral therapy that prevents the buildup of toxins in the eye that cause Stargardt disease and atrophic age-related macular degeneration, received orphan drug designation from the FDA in 2017.

“Adding orphan designation in Europe to the recent orphan drug designation in the United States marks another important regulatory milestone in the development program for LBS-008,” Lin BioScience CEO Tom Lin, PhD, said in the release. “We look forward to receiving our interim phase 1 clinical trial results later this year.”